HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
PARP inhibitors in prostate cancer: Choices of tests and how to test?
Dr Kim Chi and Dr Alexander Wyatt
11 Jun 2020
ASCO 2020 prostate cancer highlights
Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl
10 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
9 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
5 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
5 Jun 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient path...
Dr Neal Shore and Dr Elena Castro
5 Jun 2020
New emerging treatment options and targeted therapies for bladder cancer
Dr Arlene Siefker-Radtke and Dr Yohann Loriot
4 Jun 2020
EAU guidelines for treating patients with advanced prostate cancer
Dr Eleni Efstathiou, Prof Álvaro Pinto, Prof Nicolas Mottet and Prof Heather Pay...
31 May 2020
Association of BRCA alterations with response to PARP inhibitors in metastatic c...
Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...
30 May 2020
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progres...
Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia
30 May 2020
